Vicore Pharma Holding AB (publ) (FRA:6Y4)

Germany flag Germany · Delayed Price · Currency is EUR
0.908
+0.020 (2.25%)
At close: Dec 4, 2025
49.10%
Market Cap 264.12M
Revenue (ttm) 768.92K
Net Income (ttm) -38.39M
Shares Out n/a
EPS (ttm) -0.17
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume n/a
Open 0.908
Previous Close 0.888
Day's Range 0.908 - 0.908
52-Week Range 0.521 - 1.182
Beta n/a
RSI 46.61
Earnings Date Feb 27, 2026

About Vicore Pharma Holding AB

Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary arterial hypertension. It also developing Almee, an investigational medical device in clinical development that has completed Pha... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2000
Employees 29
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 6Y4
Full Company Profile

Financial Performance

Financial numbers in SEK Financial Statements

News

There is no news available yet.